Benefits
Blood Sugar Regulation
In a pooled analysis of 27 randomized trials in 2,569 people with type 2 diabetes, high blood lipids or high blood pressure, berberine lowered fasting blood glucose and HbA1c compared with placebo or lifestyle changes alone. The authors' own caveat matters: because the included studies were of limited quality, they said the benefit can be substantiated only to a limited degree. Everyone studied had a diagnosed condition, so this is not a demonstrated effect in healthy people, and berberine is not a treatment for diabetes. The AMPK pathway usually offered as the explanation comes from laboratory work, not from these trials.
Cardiovascular Health
In that same 27-trial pooled analysis, and in a separate pooled analysis of 10 trials in 811 people with fatty liver disease, berberine lowered total cholesterol, LDL cholesterol and triglycerides compared with control. Blood pressure came down modestly in the first analysis. Both reviews studied people already diagnosed with a metabolic or liver condition, and neither measured heart attacks, strokes or any other heart event, so the effect on actual heart health is unknown.
Weight Management
The only cited support here is modest: in the pooled analysis of 10 trials in 811 people with fatty liver disease, BMI came down slightly (a standardized mean difference of -0.58). No cited study measured appetite, and none tested berberine as a weight loss product in healthy people. Treat it as a small side effect of metabolic changes in patients, not a weight loss supplement.
Gut Health
Berberine slows or kills some bacteria in laboratory tests, and barberry and goldenseal have a long traditional use for digestive complaints. None of the studies cited on this page measured gut bacteria, digestion or diarrhea, so this remains a laboratory idea rather than a demonstrated effect in people. In practice berberine more often causes digestive upset, including diarrhea or constipation, than relieves it.
Anti-inflammatory and Antioxidant Effects
In laboratory studies berberine dampens signaling pathways involved in inflammation, and one 34-person pilot in prediabetes reported lower inflammatory markers in the blood. The cited human research measured blood sugar, cholesterol and liver enzymes, not arthritis or any other inflammatory disease, so nothing on this page supports a conclusion about those conditions.
Mechanism of action
Activation of AMPK (AMP-activated Protein Kinase)
In cell and animal studies berberine activates AMPK, an enzyme that helps control how cells use energy. In those models this increases glucose uptake and fat burning. It is the leading explanation for the blood sugar and cholesterol changes seen in the human trials, but none of those trials actually measured AMPK, so it stays a proposed mechanism.
Inhibition of Mitochondrial Function
Berberine inhibits complex I of the mitochondrial respiratory chain, reducing ATP production. This triggers AMPK activation indirectly and may contribute to its metabolic effects.
Antimicrobial Activity
In laboratory tests berberine damages bacterial cell membranes and interferes with microbial DNA copying. Whether that changes gut bacteria in a person taking a supplement was not tested in any study cited on this page.
Regulation of Gene Expression
In laboratory models berberine acts on transcription factors such as PPARs and dampens the pro-inflammatory NF-kB pathway. These findings come from cell and animal work; inflammation and oxidative stress were not measured as outcomes in the human trials cited here.
Inhibition of Enzymes
In laboratory work berberine blocks PCSK9, an enzyme involved in clearing LDL cholesterol, and alpha-glucosidase, which breaks down carbohydrates. These are proposed explanations for the cholesterol and blood sugar changes measured in the trials, not findings from the trials themselves.
Gut Microbiota Modulation
Animal and laboratory studies report shifts in gut bacteria with berberine. No study cited on this page measured gut bacteria in people, so this stays a hypothesis rather than a demonstrated effect.
Poor Absorption
Only a small fraction of an oral berberine dose reaches the bloodstream, roughly 5 percent. That is why doses are large and split through the day, why manufacturers keep trying alternative forms, and part of why results differ so much from study to study.
Clinical trials
Systematic review and meta-analysis of 27 randomized controlled trials including 2,569 patients, testing berberine alone or alongside lifestyle changes in type 2 diabetes, high blood lipids and high blood pressure (J Ethnopharmacol, 2015). Outcomes: HbA1c, fasting blood glucose, LDL, total cholesterol, triglycerides and blood pressure.
2,569 patients across 27 trials, all with diagnosed type 2 diabetes, high blood lipids or high blood pressure.
Berberine, alone or with lifestyle changes, lowered fasting blood glucose, HbA1c, total cholesterol, LDL cholesterol, triglycerides and blood pressure compared with placebo or lifestyle changes alone. The authors' own conclusion is the most important part: because of the overall limited quality of the included studies, the therapeutic benefit of berberine can be substantiated only to a limited degree. Poor absorption, roughly 5 percent of an oral dose, remains a major limitation.
Randomized, double-blind, placebo-controlled Phase 2 proof of concept trial (NCT03656744) in 100 patients with presumed non-alcoholic steatohepatitis and type 2 diabetes, over 18 weeks (Nat Commun, 2021). Important: HTD1801 is not a berberine supplement. It is a first-in-class investigational drug from HighTide Therapeutics in which berberine is chemically paired with ursodeoxycholic acid, itself a prescription medicine used for gallstones and liver disease.
100 adults with presumed non-alcoholic steatohepatitis and type 2 diabetes, 18 weeks.
At 1,000 mg twice daily, liver fat fell further than with placebo, down 4.8 percent versus 2.0 percent (p=0.011). These results belong to the investigational two-ingredient drug and do not transfer to a berberine supplement.
Randomized, double-blind, placebo-controlled pilot trial in 34 adults with prediabetes taking HIMABERB berberine 1,500 mg per day or placebo for 12 weeks. The authors themselves describe it as a pilot. Outcomes: fasting glucose, HbA1c, lipid profile, body composition. (BMC Endocr Disord, 2023)
34 adults with prediabetes, 12 weeks.
Fasting blood glucose, HbA1c and inflammatory markers improved compared with placebo, and the supplement was well tolerated. With 34 people over 12 weeks in a study the authors call a pilot, this is an early signal in people with prediabetes, not proof of a benefit and not a reason to delay medical care.
Systematic review and meta-analysis of 10 randomized controlled trials including 811 patients with non-alcoholic fatty liver disease, looking at liver enzymes, blood lipids, insulin resistance and BMI (J Transl Med, 2024).
811 patients with diagnosed non-alcoholic fatty liver disease across 10 trials.
Berberine improved liver enzymes (ALT, AST, GGT), triglycerides, total cholesterol, LDL cholesterol, insulin resistance (HOMA-IR) and BMI compared with control, and only mild digestive side effects were reported. Formulations and doses varied a lot between the included studies. The authors suggest berberine as an add-on for fatty liver disease pending larger trials, which is a decision for the doctor managing that diagnosis, not a general consumer recommendation.
Phase 2 multicenter, randomized, double-blind, placebo-controlled trial in 113 Chinese adults with type 2 diabetes (38 on placebo, 37 on 500 mg, 38 on 1,000 mg) over 12 weeks (JAMA Netw Open, 2025). As with the liver trial above, berberine ursodeoxycholate pairs berberine with the prescription medicine ursodeoxycholic acid and is an investigational drug, not a supplement.
113 Chinese adults with type 2 diabetes, 12 weeks.
HbA1c fell by 0.4 percent on 500 mg and by 0.7 percent on 1,000 mg compared with placebo over 12 weeks. The trial never compared this drug against ordinary berberine, so it says nothing about how a berberine supplement would perform.
Randomized, double-blind, placebo-controlled trial in people with schizophrenia who were taking antipsychotic medication and received berberine 900 mg per day or placebo for 8 weeks. 65 people enrolled and 49 finished. Outcomes: glycolipid metabolism (FPG, lipids, insulin), weight, antipsychotic-induced metabolic side effects. (2021, Psychiatry Research)
65 people with schizophrenia on antipsychotic medication, 49 of whom completed the 8 week study.
Total cholesterol, LDL cholesterol, fasting insulin and insulin resistance improved compared with placebo. This study is about blunting the metabolic side effects of antipsychotic medication in people with a serious mental illness under specialist care. It says nothing about what berberine does for a healthy person, and anyone taking antipsychotics should only consider berberine with their psychiatrist, since it can also change blood levels of other medicines.